Influenza vaccine information for health professionals

For the 2025/2026 influenza season in Canada, and in alignment with public health and regulatory agencies globally, all available influenza vaccine products will be trivalent (TIV) formulations. 

The National Advisory Committee on Immunization (NACI) advises that the following individuals are at a higher risk of influenza-related complications or are more likely to require hospitalization and should receive the vaccine as soon as it becomes available:

• residents of congregate living settings (such as chronic care facilities, retirement homes)
• people 65 years of age and over
• all pregnant women
• all children 6 months to 4 years of age
• individuals in or from First Nations, Métis or Inuit communities
• individuals 6 months of age and older with the following underlying health conditions:
• cardiac or pulmonary disorders
• diabetes mellitus or other metabolic disease
• cancer
• conditions or medication which compromise the immune system
• renal disease
• anemia or hemoglobinopathy
• neurologic or neurodevelopment conditions
• morbid obesity (body mass index of 40 or more)
• children and adolescents (6 months to 18 years) undergoing treatment with acetylsalicylic acid for long periods

Priority populations

To optimize co-administration with COVID-19 vaccine, the following individuals may receive influenza vaccine as soon as it becomes available in the fall:

• Staff and care providers in congregate living settings (for example, long-term care homes, chronic care facilities)
• Health-care workers
• First responders
• Members of underserved communities
• Individuals with significant exposure to birds or mammals
• This includes those likely to have significant exposure to influenza A(H5N1) through interactions with birds or mammals (such as poultry, livestock, slaughterhouse and processing plant workers, wildlife officers/researchers, and veterinarians). Seasonal influenza vaccines do not provide protection against infection with influenza A(H5N1) viruses. However, they may reduce the risk of seasonal human and influenza A(H5N1) virus co-infection and possible viral reassortment leading to a human-transmissible virus with pandemic potential.

Two particularly recommended groups

The influenza vaccine is recommended for all individuals 6 months of age and older without contraindications. However, individuals in the following 2 groups are particularly recommended to receive the influenza vaccine and should receive the vaccine starting October 27, 2025.

1. Individuals capable of transmitting influenza to those listed in the high-risk group above and/or to infants under 6 months of age
• care providers in the community
• household contacts (adults and children) of individuals at high risk of influenza related complications
• persons who provide care to children 4 years of age and under
• members of a household expecting a newborn during the influenza season
• those who provide services within a closed or relatively closed setting to persons at high risk of influenza related complications (crew on a ship, for example)
2. People who provide essential community services

How many vaccine doses are required?

Two doses are recommended for children six months to under nine years of age receiving seasonal influenza vaccine for the first time in their life, with a minimum interval of four weeks between doses. All others require only one dose annually.

Influenza vaccine is contraindicated in:

• Persons who have developed Guillain-Barré Syndrome (GBS) within six weeks of influenza vaccination, unless another cause was found for the GBS.
• Persons who have developed an anaphylactic reaction to a previous dose of influenza vaccine or to any of the vaccine’s components, except for egg.
  • Egg-allergic individuals may be vaccinated against influenza without prior influenza vaccine skin test and with the full dose, irrespective of a past severe reaction to egg, and without any extraordinary precautions, but ensuring that, as with all vaccine administration, immunizers be prepared with the necessary equipment, knowledge and skills to respond to a vaccine emergency always.
  • In situations of suspected hypersensitivity or non-anaphylactic allergy to a vaccine or its components, investigation is indicated which may involve immunization in a controlled setting. Consultation with an allergist is advised. If an individual is found to have an anaphylactic reaction to a component in one influenza vaccine, consideration may be given to offering another influenza vaccine that does not contain the implicated component, in consultation with an allergy expert. Individuals who have an allergy to substances that are not components of the influenza vaccine are not at increased risk of allergy to influenza vaccine

For more information on contraindications and precautions, please consult the product monographs:

• Fluviral trivalent 
• Fluzone Standard-Dose trivalent
• Flucelvax trivalent
• Fluzone High-Dose trivalent
• Fluad

Vaccine Distribution Centre hours are Monday to Friday, 8 am to 4 pm.

NOTE: On all Statutory holidays The Vaccine Distribution Centre is closed.

1. To order vaccine, please use the: Immunization related forms for health professionals - Ottawa Public Health (not the Ministry of Health form).
2. When placing the order, please complete the number of doses required and the doses on hand. Place your order by completing the number of doses required on the form. Orders will be filled in the order in which they are received, with priority to high-risk groups. The first auto-shipment will contain a predetermined amount of vaccine to be shipped to vaccinate high-risk patients. Additional influenza orders can be placed on or after October 14th. Please allow up to five business days for your order to be processed.
3. OPH recommends reserving some vaccine for persons aged 65 years and older, and persons under 65 with medical conditions that put them at high risk for influenza-related complications.
4. Your clinic/facility will be called when your order is ready. Please arrange to pick up your order within 48 hours of notification at the Ottawa Public Health Vaccine Distribution Centreon the ground floor of 100 Constellation Drive or at 1221 Cyrville Road, based on your clinic/facility location.
5. You will need to bring your own cooler and two ice packs per cooler.

All adverse events following administration of an influenza vaccine must be reported to Ottawa Public Health within 24 hours by fax to 613-580-9660 using the AEFI reporting form.

Find more information about what constitutes an AEFI, please see Public Health Ontario's Fact Sheet on AEFI Reporting for Health Care Providers or Public Health Ontario's webpage on Vaccine Safety. If you have any questions related to the reporting of adverse events following immunization, please call 613-580-6744 and select “1” for English then “2” for healthcare provider; your call will be prioritized for answer by the next available public health nurse.

Ottawa Public Health seeks to support you in your efforts to increase influenza vaccine uptake in your facility or workplace by offering information and resources.

In you cannot find the information you seek here, please call 613-580-6744 and select “1” for English then “2” for healthcare provider; your call will be prioritized for answer by the next available public health nurse.

Information from the Ministry of Health on the 2025/2026 Universal Influenza Immunization Program (UIIP) is also available. 

Return unused vaccine to the Ottawa Public Health Immunization Program once you are finished immunizing for the season using Ottawa Public Health Vaccine Return Form.

• Ministry of Health (MOH)
  • Ministry of Health Universal Influenza Immunization Program (UIIP)
• Ottawa Public Health
  • For questions regarding a vaccine order email vaccine@ottawa.ca  or call 613-580-6744 and follow prompts for the Vaccine Distribution Centre.
  • Fax the Adverse Event Following Immunization (AEFI) reporting form to 613-580-9660
  • Hospitals, long-term care, retirement homes call the outbreak reporting line 613-580-6744 ext 26325 to report outbreaks
  • Workplaces call 613-580-6744 and select “1” for English then “2” for healthcare provider; your call will be prioritized for answer by the next available public health nurse.
  • Influenza vaccine manufacturers’ contact information:
    • Sanofi Pasteur (Fluzone^® Trivalent and Fluzone®High-Dose) 1-888-621-1146
    • GlaxoSmithKline, Inc. (Fluviral^®) 1-800-387-7374
    • Seqirus Canada Inc. ( Flucelvax^® and Fluad®) 1-855-358-8966
  • To receive information about local health issues and direction during health emergencies, please subscribe to receive Ottawa Public Health Alerts for Health Care professionals. You may also select to receive the Physicians’ Update electronic newsletter.
• Patient Resources
  • Patient information: OPH’s web page for Influenza (Flu)
  • For the latest public health information, your patients can contact Ottawa Public Health Information Centre at 613-580-6744 (TTY: 613-580-9656) or on Facebook and x (@ottawahealth). Patients can also get help connecting to programs and services by calling 811.